Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2009-11-25
2011-11-15
Aeder, Sean E (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Reexamination Certificate
active
08057799
ABSTRACT:
Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
REFERENCES:
patent: 4522918 (1985-06-01), Schlom et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6790614 (2004-09-01), Pippig et al.
patent: 6949245 (2005-09-01), Sliwkowski
patent: 7638598 (2009-12-01), Greene et al.
patent: 2010/0076174 (2010-03-01), Greene et al.
patent: WO 98/17797 (1998-04-01), None
patent: WO 01/00244 (2001-01-01), None
patent: WO 02/081649 (2002-10-01), None
Gura (Science, 1997, 278:1041-1042.).
Alroy et al., “The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions”, FEBS Letters, Jun. 23, 1997, 410(1), 83-86.
Bach et al., “Structural Studies of a Family of High Affinity Ligands for GPIIb/IIIa”, J. of American Chemical Society, Apr. 1994, 116(8), 3207-3219.
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation”, Cell, May 7, 1993, 73(3), 431-445.
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2
eu Overexpressing Human Breast Cancer Xenografts”, Cancer Research, Jul. 1, 1998, 58(13), 2825-2831.
Berezov et al., “Disabling erbBReceptors with Rationally Designed Exocyclic Mimetics of Antibodies: Structure-Function Analysis”, J. of Medicinal Chemistry, Aug. 2, 2001, 44(16), 2565-2574.
Berezov et al., “Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics”, J. of Biological Chemistry, Aug. 2, 2002, 277(31), 28330-28339.
Blain et al., “Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4”, J. Bio. Chem., Oct. 10, 1997, 272(41), 25863-25872.
Brennan et al., “HER2/Neu: mechanisms of dimerization/oligomerization”, Oncogene, Dec. 11, 2000, 19(53), 6093-6101.
Britsch et al., “The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system”, Genes Dev., Jun. 15, 1998, 12(12), 1825-1836.
Brown et al., “Demonstration by Two-Color Flow Cytometry That Tyrosine Kinase Activity Is Required for Down-Modulation of the Oncogenic neu Receptor”, DNA Cell Biology, Feb. 1994, 13(2), 193-209.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 From Its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue”, J. of Cell Biology, Nov. 1, 1990, 111(5), 2129-2138.
Burgess et al., “In Solid Phase Syntheses of Oligoureas”, American Chemical Society, Orgn., Feb. 19, 1997, 119(7), 1556-1564.
Cambier, “Inhibitory Receptors Abound”, Proc. Natl. Acad. Sci. USA, Jun. 10, 1997, 94(12), 5993-5995.
Capone et al., “Relationship Between Antigen Density and Immunotherapeutic Response Elicited by Monoclonal Antibodies”, JNCI, Mar. 1984, 72(3), 673-677.
Carraway et al., “Location of the Epidermal Growth Factor Binding Site on the EGF Receptor: A Resonance Energy Transfer Study”, Biochemistry, Sep. 1990, 29(37), 8741-8747.
Carraway et al., “A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling”, Cell, Jul. 15, 1994, 78(1), 5-8.
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”, Proc. Natl. Acad. Sci. USA, May 15, 1992, 89(10), 4285-4289.
Chang et al., “Ligands for ErbB-family receptors encoded by a neuregulin-like gene”, Nature, May 29, 1997, 387(6632), 509-512.
Chiri et al., “Evidence for MAP kinase activation during mitotic division”, J. Cell Sci., Sep. 1998, 111(pt. 17), 2519-2527.
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, J. Mol. Biol., Aug. 20, 1987, 196(4), 901-917.
Christodoulides et al., “Immunization With Synthetic Peptides Containing Epitopes of the Class 1 Outer-Membrane Protein of Neisseria Meningitidis: Production of Bactericidal Antibodies on Immunization With a Cyclic Peptide”, J. of General Microbiology, Aug. 1993, 139(8), 1729-1738.
Cohen et al., “A Native 170,000 Epidermal Growth Factor Receptor-Kinase Complex From Shed Plasma Membrane Vesicles”, J. of Biological Chemistry, Feb. 10, 1982, 257(3), 1523-1531.
Decanniere et al., “A Single-Domain Antibody Fragment in Complex With RNase A: Non-Canonical Loop Structures and Nanomolar Affinity Using Two CDR Loops”, Structure, Apr. 15, 1999, 7(4), 361-370.
Daeron et al., “The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation”, Immunity, Nov. 1995, 3(5), 635-646.
Dahia et al., “Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours”, Oncogene, Jan. 8, 1998, 16(1), 69-76.
D'Ambrosio et al., “The SHIP phosphatase becomes associated with Fc gammaRIIB1 and is tyrosine phosphorylated during ‘negative’ signaling”, Immunology Letters, Dec. 1996, 54(2-3), 77-82.
Davies et al., “Antibody VH Domains As Small Recognition Units”, Nature Biotechnology, May 1995, 13(5), 475-479.
Davies et al., “Single Antibody Domains As Small Recognition Units: Design and in vitro Antigen Selection of Camelized, Human VH Domains With Improved Protein Stability”, Protein Engineering Design and Selection, Jun. 1996, 9(16), 531-537.
Deb et al., “A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation”, J. Biol. Chem., Jul. 3, 1998, 273(27), 16643-16646.
Deveraux et al., “X-linked IAP is a direct inhibitor of cell-death proteases”, Nature, Jul. 17, 1997, 388(6639), 300-304.
Di Cristofano et al., “The multiple roles of PTEN in tumor suppression”, Cell, Feb. 18, 2000, 100(4), 387-390.
Di Cristofano et al., “Impaired Fas response and autoimmunity in Pten+/− mice”, Science, Sep. 24, 1999, 285(5436), 2122-2125.
Doherty et al., “The HER-2
eu Receptor Tyrosine Kinase Gene Encodes a Secreted Autoinhibitor”, PNAS, Sep. 14, 1999, 96(19), 10869-10874.
Dougall et al., “The neu-Oncogene: Signal Transduction Pathways, Transformation Mechanisms and Evolving Therapies”, Oncogene, Aug. 1994, 9(8), 2109-2123.
Drebin et al., “Development of Monoclonal Antibodies Reactive With the Product of the neu Oncogene”, Symposium on Fundamental Cancer Research, (no month available) 1986, 38, 277-289.
Drebin et al., “Inhibition of Tumor Growth by a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen”, Proc. Natl. Acad. Sci. USA, Dec. 1, 1986, 83(23), 9129-9133.
Drebin et al., “Monoclonal antibodies reactive with distinct domains of the neu oncogene-encod
Berezov Alan
Chen Jinqiu
Greene Mark I.
Liu Qingdu
Murali Ramachandran
Aeder Sean E
The Trustees Of The University Of Pennsylvania
Woodcock & Washburn LLP
LandOfFree
ErbB interface peptidomimetics and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ErbB interface peptidomimetics and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ErbB interface peptidomimetics and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291804